Cargando…

Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 – The role of anti-Xa monitoring

Detalles Bibliográficos
Autores principales:	Kofteridis, Diamantis P., Ioannou, Petros, Kondili, Eumorfia, Chamilos, Georgios, Filippatos, Theodosios D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084277/ https://www.ncbi.nlm.nih.gov/pubmed/33933565 http://dx.doi.org/10.1016/j.cmi.2021.04.024

Ejemplares similares

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
por: Ioannou, Petros, et al.
Publicado: (2023)

COVID-19 in Older Individuals Requiring Hospitalization
por: Ioannou, Petros, et al.
Publicado: (2022)

Bedside anti-Xa measurement for therapeutic assessment of a prophylactic anticoagulation regimen
por: Dewulf, B, et al.
Publicado: (2013)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Special Issue: Recent Research on Hospital-Acquired Bloodstream Infections
por: Ioannou, Petros, et al.
Publicado: (2023)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Special Issue: “Current Trends and Outcomes of Infective Endocarditis”
por: Ioannou, Petros, et al.
Publicado: (2023)

Venous Thromboembolism in Hospitalized Patients With COVID-19 Receiving Prophylactic Anticoagulation
por: Boonyasai, Romsai T., et al.
Publicado: (2020)

COVID-19 and antimicrobial stewardship: What is the interplay?
por: Spernovasilis, Nikolaos A., et al.
Publicado: (2020)

Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
por: Honore, Patrick M., et al.
Publicado: (2020)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Pseudomonas Bacteremia in a Tertiary Hospital and Factors Associated with Mortality
por: Ioannou, Petros, et al.
Publicado: (2023)

Endocarditis in Liver Transplant Recipients: A Systematic Review
por: Ioannou, Petros, et al.
Publicado: (2021)

Antimicrobial Peptides in Infectious Diseases and Beyond—A Narrative Review
por: Ioannou, Petros, et al.
Publicado: (2023)

Infective Endocarditis by Yersinia Species: A Systematic Review
por: Ioannou, Petros, et al.
Publicado: (2021)

Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
por: Bachlitzanaki, Maria, et al.
Publicado: (2023)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii
por: Karakonstantis, Stamatis, et al.
Publicado: (2021)

Infective Endocarditis by Moraxella Species: A Systematic Review
por: Ioannou, Petros, et al.
Publicado: (2022)

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis
por: Loffredo, Lorenzo, et al.
Publicado: (2022)

Impact of Molecular Syndromic Diagnosis of Severe Pneumonia in the Management of Critically Ill Patients
por: Stafylaki, Dimitra, et al.
Publicado: (2022)

The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2021)

Long COVID-19 Pathophysiology: What Do We Know So Far?
por: Tziolos, Nikolaos-Renatos, et al.
Publicado: (2023)

Etiology of Anemia and Risk Factors of Mortality among Hospitalized Patients: A Real-Life Retrospective Study in a Tertiary Center in Greece
por: Ioannou, Petros, et al.
Publicado: (2023)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

An Unexpected Cause of Bradycardia in a Patient with Bacterial Meningitis
por: Ioannou, Petros, et al.
Publicado: (2017)

In elderly population prophylactic anticoagulation favors early detection of digestive track cancers: an observational study in eastern Poland
por: Szlendak, Malgorzata, et al.
Publicado: (2019)

Anti-Xa activity and hemorrhagic event: isn’t it time to consider time ?
por: Redant, Sébastien, et al.
Publicado: (2021)

Candida Species Isolation from Hospitalized Patients with COVID-19—A Retrospective Study
por: Ioannou, Petros, et al.
Publicado: (2022)

Clinical experience of prophylactic enoxaparin dosage adjustment guided by AntiXa factor levels in critical care patients with COVID-19-induced pneumonia: observational study()
por: Bermúdez-Ruiz, María del Carmen, et al.
Publicado: (2023)

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
por: Ioannou, Petros, et al.
Publicado: (2023)

Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series
por: Pannucci, Christopher J., et al.
Publicado: (2016)

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
por: Yentz, Sarah, et al.
Publicado: (2015)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Prophylactics of Osteoporosis
por: IVANOVA, Stefka, et al.
Publicado: (2020)

Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece
por: Spanakis, Marios, et al.
Publicado: (2022)

Anticoagulants and Anti-platelet Agents in Palliative Home Healthcare
por: Wiwanitkit, Viroj
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mrh4utjvrb11krstk3e7ve1g9o